

Entecavir Accord

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
R/0011	Renewal of the marketing authorisation.	22/04/2022	01/07/2022	SmPC, Labelling, Annex II and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Entecavir Accord in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.



² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. ³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

IA/0012/G	This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	17/03/2022	n/a		
IA/0010	A.7 - Administrative change - Deletion of manufacturing sites	21/12/2021	04/03/2022	Annex II and PL	
IB/0009/G	This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	14/01/2021	04/03/2022	SmPC and PL	
IA/0008	B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold	28/09/2020	n/a		

	compared to the originally approved batch size				
IB/0007	B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	08/06/2020	n/a		
IAIN/0006	B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer	24/07/2019	n/a		
T/0004	Transfer of Marketing Authorisation	18/01/2019	25/02/2019	SmPC, Labelling and PL	
IB/0005	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	30/01/2019		SmPC	
II/0001	B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range	18/10/2018	n/a		
IA/0003	B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier	08/10/2018	n/a		
IAIN/0002	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer	08/10/2018	25/02/2019	Annex II and PL	

responsible for importation and/or batch release -Not including batch control/testing